COVID-19: Considerations for impairment testing
COVID-19: Considerations for impairment testing
Key issues to consider in conducting an impairment review under COVID-19
The outbreak of COVID-19 is placing unprecedented pressures on the communities and businesses. The deterioration of the financial performance or sharp drop in stock price which leading to the market capitalisation dropped below their net book value are likely to be triggering events for impairment testing under IAS 36.
This publication sets out the key considerations in conducting an impairment review in response to the potential challenges under the current market environment.
© 2024 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in Chinese Mainland, KPMG, a Macau (SAR) partnership, and KPMG, a Hong Kong (SAR) partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
The KPMG name and logo are trademarks used under license by the
independent member firms of the KPMG global organisation.
For more detail about the structure of the KPMG global organisation please visit https://kpmg.com/governance.